- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Matthew Fowler | Authors
Articles
Extrapleural Pneumonectomy After Radiation Produced Durable Survival and Was Considered Safe for Malignant Pleural Mesothelioma
February 26, 2021
Data published in The Lancet Oncology investigating patients with malignant pleural mesothelioma determined that surgery for mesothelioma after radiotherapy, or SMART, can produce positive early- and long-term effects.
Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer
February 25, 2021
Data published in The Lancet Oncology found that a hypofractionated radiation schedule of 55 Gy in 20 fractions is noninferior to a schedule of 64 Gy in 32 fractions for patients with this disease.
Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures
February 25, 2021
Data examining 4 low-value breast cancer procedures found an association between facility-level characteristics and the use of these procedures, suggesting a need for de-implementation targeting efforts in various facilities.
PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer
February 24, 2021
The PHERGain II trial will investigate the treatment of patients with early HER2-positive breast cancer using a chemotherapy-free treatment approach of trastuzumab plus pertuzumab.
Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia
February 24, 2021
A study published in The Lancet Hematology found an increased risk of developing myelodysplastic syndrome and acute myeloid leukemia when patients with cancer were treated with PARP inhibitors compared with placebo.
Former CMO and Execute VP of ASCO on Molecular Profiling in GI Cancer and Health Inequity
February 23, 2021
Richard Schilsky, MD, touched on the research driving ASCO to award “Advance of the Year” to molecular profiling in gastrointestinal cancers, and what the organization’s top priorities are in the near future.
FDA Grants Fast Track Designation to GEN-1 Immunotherapy for Treatment of Advanced Ovarian Cancer
February 22, 2021
Celsion Corporation announced that fast track designation was granted to their immunotherapy, GEN-1, to treat patients with advanced stage III or IV ovarian cancer.
Adjuvant Pazopanib Does Not Improve Overall Survival for Patients With Locally Advanced RCC
February 22, 2021
Follow-up data published in the European Association of Urology did not find a significant improvement in overall survival for patients with locally advanced renal cell carcinoma undergoing adjuvant pazopanib treatment.
Prioritizing AEs May Lead to Improvement in Communication Between Patients With CLL and Their Oncologists
February 19, 2021
Data published in Patient Preference and Adherence found communication improved between patients with CLL and their oncologists when the risk of adverse events and patient goals were top of mind.
Black Women With Node-Negative Breast Cancer More Likely to Have High-Risk Recurrence Scores Than Non-Hispanic White Women
February 18, 2021
A retrospective, population-based cohort study in JAMA Oncology found Black women in the United States were more likely to have a high-risk recurrence score and die of axillary node-negative breast cancer than non-Hispanic White women who had similar scores.